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Background: In order to prevent outbreaks from wild and vaccine-derived poliovirus, maintenance of
population immunity in non-endemic countries is critical.
Methods: We estimated population seroprevalence using dried blood spots collected from 4893 children
6–59 months olds in the 2013–2014 Demographic and Health Survey in the Democratic Republic of the
Congo (DRC).
Results: Population immunity was 81%, 90%, and 70% for poliovirus types 1, 2, and 3, respectively. Among
6–59-month-old children, 78% reported at least one dose of polio in routine immunization, while only
15% had three doses documented on vaccination cards. All children in the study had been eligible for
at least two trivalent oral polio vaccine campaigns at the time of enrollment; additional immunization
campaigns seroconverted 5.0%, 14%, and 5.5% of non-immune children per-campaign for types 1, 2,
and 3, respectively, averaged over relevant campaigns for each serotype.
Conclusions: Overall polio immunity was high at the time of the study, though pockets of low immunity
cannot be ruled out. The DRC still relies on supplementary immunization campaigns, and this report
stresses the importance of the quality and coverage of those campaigns over their quantity, as well as
the importance of routine immunization.
 2017 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Poliomyelitis (polio) is an infectious disease caused by the
poliovirus. Like other enteroviruses, poliovirus is transmitted pri-
marily by the fecal-oral route. Poliomyelitis can affect individuals
of any age, but primarily involves children aged less than five
years. In < 1% of those infected, the virus invades the central ner-
vous system and can cause muscle weakness and acute flaccid
paralysis (AFP), usually in the lower limbs, though occasionally
progressing to breathing difficulty, and even death [1]. At the time
of writing, wild poliovirus (WPV) type 1 continues to circulate in
Nigeria, Pakistan, and Afghanistan. WPV type 2 was last seen in
1999, while WPV type 3 was last seen in 2012 [2].Poliomyelitis is preventable using injectable inactivated polio
vaccines (IPV) and live attenuated oral polio vaccines (OPVs)
[1,3]. For the Global Polio Eradication Initiative (GPEI), whose
mission is complete eradication and containment of all wild and
vaccine-related polioviruses, OPV is the vaccine of choice due to
its low cost, ease of delivery, and improved ability to prevent
person-to-person transmission [1]. Prior its global withdrawal in
April 2016, trivalent OPV (tOPV) was the most commonly used vac-
cine, providing protection against all three serotypes of poliovirus
[1]. Bivalent and monovalent formulations were also used in
response to prevalent strains of circulating poliovirus. In April
2016, type 2 containing tOPV was removed from use globally in
order to prevent rare adverse events associated with its use,
including vaccine-associated paralytic poliomyelitis, and
emergence of circulating vaccine-derived poliovirus type 2
(cVDPV2) [4].
5694 A. Voorman et al. / Vaccine 35 (2017) 5693–5699In the DRC, the Expanded Program on Immunization (EPI) was
introduced in 1978, with the childhood vaccination schedule for
polio including four doses of tOPV at birth, 6, 10 and 14 weeks of
age. The DRC’s Polio Eradication Program led by the country’s EPI
started in 1996, providing additional doses of OPV through house-
to-house supplemental immunization activities (SIAs) in areas of
the countrywithahighburdenof disease.Until 2001,DRCwasende-
mic for WPV transmission, and was considered a reservoir and
exporter of virus to other countries. From 2001 to 2005, no WPV
cases were reported in the DRC, and the interruption of WPV trans-
missionwas assumed. However, between 2006 and 2011, outbreaks
ofWPV1andWPV3were reported in 10 of 11provinces as a result of
numerous importations from Angola (Fig. 1). In addition, over 10
independent emergences of cVDPV2 were documented during
2004–2012 [5]. The last confirmed WPV case reported in Maniema
province with an onset of 20 December 2011. More recently, two
cVDPV2 outbreaks were declared in 2016, originating in Maniema
and Haut Lomami (formerly Katanga) provinces.
Given the historical importation of poliovirus into DRC and fre-
quent VDPV emergences, achieving and maintaining high popula-
tion immunity is critical to the success of the GPEI. While
immunization campaign coverage monitoring provides operational
oversight of individual activities, it gives limited information about
their cumulative effect. Vaccination history, when collected, may
be highly biased due to imperfect and variable recording and recallFig. 1. Epidemiology and polio vaccination program history in the DRC. Top panel: the ge
placed randomly in the district where a child was present two weeks prior to the onset o
counts are bars representing supplemental immunization activities. The grey band show[6,7]. Additionally, even if vaccination history could be obtained,
estimates of protective efficacy from polio vaccination vary widely,
for instance, between 30 and 100% for 3 doses of tOPV [8]. Lastly,
secondary spread of vaccine viruses to contacts of vaccine recipi-
ents contributes to population immunity, but varies with popula-
tion characteristics and is therefore difficult to account for in the
absence of immunological data [9]. Therefore, in order to measure
the effectiveness of polio immunization activities and identify pop-
ulations with sub-optimal immunity, serologic assessment of the
population is critical.
Nationally representative serologic studies of polio immunity
have not been conducted in the DRC, or in the African region more
broadly. There have been some targeted assessments of polio
immunity, including recent studies in northern Nigeria, India,
western China, and Pakistan [10–14]. In addition, there was a
large-scale polio serosurvey in the United States from 2009 to
2010 [15], and a 2013 nutrition survey in Afghanistan which
included polio serology [16]. In the DRC, Alleman et al. studied
seroprevalence among adult women prior to an outbreak of
WPV1 in 2010 and 2011, using samples obtained from ante-natal
clinics in the DRC [17]. The authors identified relatively low immu-
nity to type 1 poliovirus among adult women in Kinshasa and Ban-
dundu where the outbreak affected adults, and relatively high
immunity in Kasai-Oriental, where the WPV1 cases were exclu-
sively children.ographic distribution of cases in the periods 2006–2009 and 2010–2012; points are
f paralysis. Bottom panel: polio AFP case count by three-month bins; above the case
s the period in which the DHS survey was conducted.
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2.1. Demographic and health survey
The second Demographic and Health Survey (DHS) was con-
ducted in the DRC from August 2013 to February 2014. The house-
hold survey used a multi-stage stratified cluster design, sampling
18,171 households among 526 clusters and 66 strata, to generate
population health and social characteristics representative at the
national level, for each of the 11 provinces, and for rural and urban
populations [18,19]. Half of all households were selected for inter-
views of the adult men, and among these households children 6 to
59 months were eligible for the serological survey.
Data obtained from children included, but was not limited to,
demographics, anthropometric measures, health outcomes and
vaccination history. After parental consent, dried blood spots
(DBS) were collected by heel or finger prick from participating chil-
dren. Ethical approval was obtained at UCLA Fielding School of
Public Health, the Kinshasa School of Public Health and the Centers
for Disease Control and Prevention.2.2. Laboratory analysis
Testing for neutralizing antibodies against polio types 1, 2 and 3
was conducted at the US Centers for Disease Control and Preven-
tion [20]. We used the modified poliovirus microneutralization
assay which, like the gold standard serum neutralization assay,
measures the ability of antibodies in serum or eluted from dried
blood spot (DBS) punches to block the infectivity of poliovirus in
an in vitro cell culture system. Following collection and in-
country processing, the DBS had been stored and shipped at
20 C with desiccant. On receipt at the laboratory the specimens
were logged and randomized. Two six mm punches, equivalent to
approximately 6 ml of sera, were collected from each card and pro-
cessed for the low-volume polio neutralization assay. A series of
dilutions of dried blood spot eluate were combined with a fixed
amount of virus prior to inoculation of poliovirus-susceptible cells.
After five days incubation, a luminescent cell viability reagent was
added to detect live cells, the presence of live cells indicating pro-
tection from virus cytopathic effect which is the neutralization of
virus infectivity. The endpoint titer was calculated using a standard
formula. A neutralizing antibody titer of 1:8 correlates with protec-
tion from disease and was used as the threshold of seropositivity.
Each test was run in triplicate, with dilutions ranging from 1:8 to
1:1024. Each dried blood spot was tested for neutralizing antibod-
ies against the Sabin 1, Sabin 2, and Sabin 3 oral vaccine strains.2.3. Statistical analysis
Among 8594 eligible children, 1105 (13%) had no matching
serological data, while a further 2596 had insufficient dried blood
to perform the neutralizing assay (Fig. 2). This resulted in 4893
children available for analysis. The rate of missing data varied by
province (30% in Equateur province, to 63% in Sud-Kivu), and by
wealth index (40% in among the poorest and 49% among the rich-
est). We accounted for missing data by raking the sampling
weights so that each new province, age group, urban/rural group
carried the same marginal weight as in the 8594 children eligible
for analysis [21].
We augmented the information available in the DHS with the
number of SIAs for which the child would have been eligible prior
to the survey, noting the antigens present in the vaccine used. SIAs
are organized by health district, which is not recorded in the DHS.
We determined health districts from the DHS clusters’ GPS coordi-
nates mapped onto health district boundaries used by the polioprogram. GPS coordinates were not available for 45 of the 536 clus-
ters, and resulted in removal of 433 children from analyses involv-
ing SIAs. The SIAs for which a child would have been eligible was
then determined by referencing the health district of the child at
the time of blood draw against the SIA database maintained by
WHO. This procedure assumes to some extent that the child lived
in the same district during those SIAs. However, most SIAs target
either the whole country or whole provinces, and thus the data
should be robust to some amount of local travel.
When analyzing routine immunization status, we used diphthe-
ria, tetanus and pertussis (DTP) vaccination as a proxy for vaccina-
tion with OPV, since they are given at the same time in the routine
schedule and DTP is less likely to be confused with vaccine
received through SIAs. This decision is consistent with previous
analyses of poliovirus risk [6,22]. We considered someone to have
‘partial’ routine immunization if they reported 1–2 doses of DTP,
by recall or by vaccination card, and full immunization if they
had 3 doses of DTP.
We estimated population immunity to each poliovirus serotype
at the national level, by province, age group, wealth index, moth-
ers’ education level, residence (rural or urban), household size,
birth order, and routine immunization status. We also estimated
population immunity to each serotype as a function of the number
of SIAs for which a child was eligible. To test whether seropreva-
lence varied by a categorical variable (province, wealth index, edu-
cation level, residence, routine immunization status), we compared
an intercept-only binomial regression to a model that allows sero-
prevalence to vary with the characteristic, using the likelihood
ratio test. For ordered numeric variables (age, household size,
and birth order), this was done with a linear term. A p-value less
than 0.05 was used to classify a result as statistically significant,
which did not account for multiple testing.
To summarize differences in seroprevalence for differences in
SIAs we used Poisson regression modified for binomial outcomes
[23]. In this model, seroprevalence S as a function of the number
of SIAs n took the form
1 SðnÞ ¼ a ð1 bÞn: ð1Þ
Here b is the proportional decrease in non-immune individuals 1-
unit difference in n. This has the convenient interpretation as the
seroconversion resulting from an additional SIA in an intention-
to-treat analysis, averaged over differences in SIA eligibility in the
population.
All analyses were performed in R version 3.2.3[24]. All analyses
account for DHS survey design using the ‘survey’ package [21].3. Results
Population immunity among 6–59-month olds to polio was 81%
(CI: 79–83%), 90% (CI: 89–91%), and 70% (CI: 68–73%), for types 1,
2, and 3, respectively (Fig. 3 and Supplementary Table S1). Immu-
nity also varied with basic demographic characteristics: for all
three polio serotypes, immunity increased with age, wealth index,
and mothers’ education, and tended to be higher in urban areas
(p < 0.05). Immunity was not associated with the gender of the
child, birth order, or household size. While immunity had a detect-
able increase with age, presumably due to SIAs and passively
acquired immunity from contact with OPV recipients, the magni-
tude of the increase was relatively small; immunity to type 1 polio-
virus was 79% among 6–11 month olds and 83% among 48–
59 month olds. We observed relatively large differences in sero-
prevalence by wealth index; for type 1 poliovirus seroprevalence
was 73% among children from the poorest households and 91%
among the richest households.
Fig. 2. Sample size resulting from applying inclusion criteria and removing missing data.
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poliovirus varied by province (Fig. 4 and Supplementary
Table S2). Immunity to each serotype was generally lower in cen-
tral DRC, and higher in the east and west, and some regional vari-
ation reflects differences in wealth and residence. For instance,
immunity to type 1 poliovirus is generally high in wealthy urban-
ized populations of Kinshasa. Not all provinces follow this trend,
however. Sampled households in Nord-Kivu were neither particu-
larly wealthy nor urbanized, but had high immunity to all three
serotypes (Supplementary Fig. S1).
We estimated the variation in seroprevalence by vaccination
activity, assessing both routine immunization status and the num-
ber of SIAs for which a child would have been eligible (Fig. 5).
Among all three polio serotypes, seroprevalence is higher among
those who have received one or more doses of DTP compared to
those who have not, whether by parental recall or vaccination card.
Those with three documented doses of DTP have higher seropreva-
lence than those who report three doses based on parental recall,
suggesting some inaccuracies in reported routine immunization
status.
Immunity is higher among children who have experienced
more SIAs. Note that all children in the study had experienced at
least two tOPV SIAs. Among children who were eligible for addi-
tional SIAs, we estimate the (intention to treat) seroconversion to
be 5.0% (CI: 4.2–5.8%), 16% (CI: 14–19%), and 5.5% (CI: 4.6–6.3%)
per SIA for types 1, 2, and 3, averaged over relevant campaigns
for each serotype.
We stratified our analysis of SIA impact by routine immuniza-
tion status (Fig. 6 and Supplementary Tables S3 and S4). Serocon-
version rates did not vary significantly with routineimmunization status (likelihood ratio test p-value > 0.05 for each
serotype, comparing model with interaction term between SIA
and DTP to a model with main-effects only). To isolate the impact
of the first two tOPV SIAs, we examined seroprevalence among
those who did not receive routine immunization and were eligible
for two (tOPV) SIAs. Among this group, seroprevalance was 56%
(40–71%), 77% (65–89%), and 42% (27–57%) for types 1, 2, and 3,
respectively.4. Discussion
Overall, our results indicate that immunity is moderately high
for all three poliovirus serotypes (81%, 90%, and 70% for Polio Types
1, 2, and 3). Immunity was higher among the wealthy, educated
and urban populations and, conversely, lower among children from
poorer, less educated, or rural households. Variation in immunity
among these demographic groups can be explained to some extent
by routine immunization status and the number of immunization
activities. For instance, 83% of those in the highest wealth quintile
reported full DTP vaccination, compared to 44% of the poorest
wealth quintile. However, there still remains substantial uncer-
tainty about routine immunization coverage and the share of
immunity that can be attributed to it, since only 19% of children
had vaccination cards.
All children in the study were eligible for at least two tOPV SIAs;
we found that immunity improved among older children who were
eligible for additional SIAs. While the increase in immunity result-
ing from these SIAs was statistically significant, the increase in
seroprevalence per-SIA was quite small, with seroconversion rates
of 5.0%, 16%, and 5.5% for types 1, 2, and 3, respectively. These rates
Fig. 3. Seroprevalence by demographic characteristics.
Fig. 4. Seroprevalence and routine immunization coverage, by province.
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internally at odds with the high seroprevalence seen in recipients
of routine immunization [8]. However, these are intention-to-
treat estimates that only pertain to SIAs beyond the first two achild experienced. One explanation is that children who are missed
in the first two SIAs are also likely to be missed in subsequent SIAs,
and hence do not seroconvert. The relatively high seroconversion
rate for type 2 OPV could then be attributed to its higher secondary
Fig. 5. Seroprevalence by routine immunization status and SIA eligibility. Note, fewer SIAs with type-2 containing vaccine were conducted than for types 1 and 3. Thus,
estimates for type 2 seroprevalence are not available for children who have experienced 11 or more SIAs.
Fig. 6. Seroprevalence by SIA eligibility, by stratified by routine immunization status. Left panel: those who report no DTP routine immunization. Right panel: those with
documented full DTP immunization.
5698 A. Voorman et al. / Vaccine 35 (2017) 5693–5699spread to children missed by the SIA, in addition to higher vaccine
efficacy. An alternative explanation is low OPV efficacy specific to
SIA delivery, perhaps due to cold-chain management. However,
seroprevalence among those who report no routine immunization
and who were eligible for two tOPV SIAs was 56%, 77%, and 42% for
types 1, 2, and 3, which suggests substantially higher seroconver-
sion from those first two SIAs. Thus it seems likely that the vast
majority of children who are not immunized after their first two
SIAs will continue to be unimmunized following subsequent SIAs,
at least for types 1 and 3. This in turn has implications for supple-
mentary vaccination policy, where the GPEI may benefit more from
increasing the quality of SIAs rather than their frequency, in addi-
tion to expanding routine immunization to less wealthy and less
educated populations.
The design of the survey gives some insight into the geographic
structure of immunity, and whether unimmunized children are
found evenly throughout the clusters, or are concentrated in ones
that are not reached by vaccinators. We estimate the intra-class
correlation (ICC) to be 0.08, 0.05, and 0.09 for types 1, 2, and 3,
respectively, after adjusting for survey strata. This moderately
low ICC suggests that deficiencies in immunity are not explained
by unvaccinated villages, but instead by dispersed unimmunized
children within relatively well-vaccinated communities.
An important milestone in polio eradication occurred in April
2016 with the removal of type-2-containing OPV from use.
Achieving high population immunity to type 2 poliovirus priorto removal of OPV2 is important to prevent emergence and trans-
mission of VDPVs [25]. Our estimate of 90% immunity to type 2
poliovirus in a survey that occurred immediately after two
national tOPV immunization campaigns was encouraging for its
general success in the DRC. However, despite overall high immu-
nity to type 2 poliovirus at the time of this survey, two separate
cVDPV emergences were recently detected, with index cases iden-
tified in Maniema province in March 2017, and in central Katanga
in April 2017 [2]. These areas had seroprevalence of 82% (74–93%)
and 89% (86–92%), respectively, and were not significantly differ-
ent from the country taken as a whole. Thus, it is possible that
immunity declined in the intervening 3 years, or that cVDPVs
emerged in pockets of low immunity that were not represented
in the survey.
A follow-up survey was conducted in August 2016 in central
Katanga, to study an area of frequent cVDPV emergence, as well
as site of one of the 2017 outbreaks. Laboratory and data analyses
from this study are ongoing will provide additional insight.
This study had several limitations. As a household-based sur-
vey, mobile or hard-to-reach populations may not be well-
represented. The study was also cross-sectional, while some esti-
mates, such as the intention-to-treat impact of an SIA, are longitu-
dinal in nature and may be biased by changes in SIA or routine
coverage over time. There was also a substantial proportion of
missing serology data, which may have affected results if related
to sero-status in a way which we did not account for.
A. Voorman et al. / Vaccine 35 (2017) 5693–5699 56995. Conclusions
Overall immunity was high at the time of the survey (2013–
2014), though recent cVDPV emergences highlight the potential
for pockets of unimmunized children. While routine immunization
appears to confer high levels of immunity, the impact of repeated
SIAs appears to be marginal. The GPEI would benefit from further
serological study of high-risk populations and assessments of
large-scale interventions such as SIAs.
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